



PATENT
Attorney Docket No.: 47508.556 (HYZ-069CN2)

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Sudhir Agrawal

Serial No.: 09/896,692 Examiner: Jane J. Zara

Filed: June 29, 2001 Group Art Unit: 1635


For: NOVEL HIV-SPECIFIC OLIGONUCLEOTIDES AND METHODS OF
THEIR USE

RECEIVED
FEB 9 2004
TECH CENTER 1600/2900

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below:

Date: February 2, 2004

By: 
Lisa A. Calder

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant and their attorney are aware of the following publications and information listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97(c) hereby submit these publications for the Examiner's consideration along with the required fee of \$180 as set forth in §1.97(c)(2) and §1.17(p).

In addition, we are re-submitting under "Other Documents" reference A21, Milner et al. (1997) "Selecting Effective Antisense Reagents On Combinatorial Oligonucleotide Arrays," *Nature Biotech.* 15:537-541, due to a typo of the year (1977) in the initial IDS filed on September 5, 2001.

02/06/2004 HAL111 0000090 080219 09896692

02 FC:1806 180.00 DA

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art. If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

The Commissioner is hereby authorized to charge any fee deficiency or credit any overpayment to Deposit Account No. 08-0219.

Respectfully submitted,

Date: February 2, 2004



James T. Olesen, Ph.D.
Registration No. 46,967
Attorney for Applicant

Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
Tel: (617) 526-6045
Fax: (617) 526-5000

Sub. Form PTO-1449 INFORMATION DISCLOSURE IN AN APPLICATION FEB 04 2004 (Use several sheets if necessary)				Docket Number 47508-556 (HYZ-069CN2)	Application Number 09/896,692
				Applicant Agrawal	
				Filing Date June 29, 2001	Group Art Unit 1635
PATENT & TRADEMARK OFFICE Sheets		1	OF	2	

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,806,463	05/1986	Goodchild et al.	435	5	
	5,470,702	01/1993	Hovanessian et al.	435	5	
	5,591,721	10/1994	Agrawal et al.	514	44	
	5,652,355	07/1997	Metelev et al.	536	24.5	
	5,652,356	07/1997	Agrawal	536	24.5	
	6,608,035	08/2003	Agrawal et al.	514	44	
	6,645,943	11/2003	Agrawal et al.	514	44-	

Foreign Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	WO96/12497	05/02/96	PCT			
	WO 98/40058	9/17/1998	PCT			

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)	
A1	Agrawal, et al. (1992) "GEM*91 – An Antisense Oligonucleotide Phosphorothioate as a Therapeutic Agent for AIDS", <i>Antisense Res. Dev.</i> 2:261-266
A2	Agrawal et al. (1994) "Potential for HIV-1 Treatment with Antisense Oligonucleotides", <i>J. Biotech. in Healthcare</i> , 1(2):167-182.
A3	Agrawal, et al. (1995) "Pharmacokinetics of Antisense Oligonucleotides", <i>Clin. Pharmacokinet.</i> 28(1):7-16
A4	Agrawal (1996) "Preface" in <i>Methods in Molecular Medicine: Antisense Therapeutics</i> (Agrawal,ed.) pp. v-vii
A5	Agrawal, et al. (1998) "Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administrations in Experimental Animals", in <i>Handbook of Experimental Pharmacology</i> , Vol. 131: <i>Antisense Research and Application</i> , Springer-Verlag, pp. 525-543
A6	Agrawal (1999) "Importance of Nucleotide Sequence and Chemical Modifications of Antisense Oligonucleotides," <i>Biochimica et Biophysica Acta</i> 1489:53-68
A7	Beaucage (1993) "Oligodeoxyribonucleotides Synthesis" in <i>Methods in Molecular Biology</i> , Vol. 20: <i>Protocols for Oligonucleotides and Analogs</i> , (Agrawal, ed.) Humana Press, Totowa, NJ, pp.33-61
A8	Brown (1993) "A Brief History of Oligonucleotide Synthesis" in <i>Methods in Molecular Biology</i> , Vol. 20: <i>Protocols for Oligonucleotides and Analogs</i> , pp. 1-17
A9	Craig et al. (1997) "Patent strategies in the antisense oligonucleotide based therapeutic approach" <i>Exp. Opin. Ther. Patents</i> 7(10):1175-1182
A10	Database CAS Registry (2003), (Date of entry: 1997), Registry number 193635-63-1
A11	Froehler (1993) "Oligodeoxynucleotide Synthesis," <i>Methods in Molecular Biology</i> , Vol. 20: <i>Protocols for Oligonucleotides and Analogs</i> (Agrawal, ed.) Humana Press, Towtowa, NJ, pp. 63-80
A12	Furdon (1989) "RNase II cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds," <i>Nucleic Acids Research</i> , Vol. 17:22, pp. 9193-9205
A13	Galderisi et al. (1999) "Antisense Oligonucleotides as Therapeutic Agents" <i>J. Cell. Physiol.</i> 181:251-257

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

EXAMINER	DATE CONSIDERED
----------	-----------------